Orexigen Therapeutics, Inc. (OREX) Bulls Wager On Sharp Gains

Orexigen Therapeutics, Inc. has been an on-chart dynamo since mid-October

Digital Content Group
Dec 15, 2014 at 2:06 PM
facebook twitter linkedin


Orexigen Therapeutics, Inc. (NASDAQ:OREX) has surged 3.8% to trade at $5.96, and calls are flying off the shelves at almost nine times the expected intraday clip. By the numbers, more than 7,700 contracts are on the tape, compared to 821 puts.

Buy-to-open activity is detected at the out-of-the-money December 7 call, where 3,680 contracts have been exchanged -- making it OREX's most active option. In other words, these traders are gambling on the stock to continue running higher through the end of this week, when front-month options expire.

Turning to technicals, OPK has rebounded sharply since hitting a two-year low of $3.11 in mid-October. Specifically, the stock has rocketed nearly 92% higher in roughly two months, during which it has outperformed the broader S&P 500 Index (SPX) by 32.6 percentage points.

If Orexigen Therapeutics, Inc. (NASDAQ:OREX) can maintain this positive momentum, the shares could benefit from a potential short-covering rally. After all, 32% of the equity's float is sold short, which would take more than three weeks to buy back, at typical daily trading volumes.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners